Sulzer IntraTherapeutics To Submit PMA For Renal Indication In Early 2002
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Medica's IntraTherapeutics unit intends to submit a premarket approval application to FDA for use of its IntraStent DoubleStrut ParaMount XS stent delivery system in the renal artery in the first quarter of 2002.
You may also be interested in...
Medtronic Bridge X3
Renal stent system gains CE mark approval for European marketing. Indicated for the treatment of atherosclerotic disease in the renal arteries, the device has a 6 Fr crossing profile and high radial strength to withstand the elastic recoil found in renal arteries, the company claims. The stent has an unexpanded length of 17 mm and comes in diameters of 5, 6, and 7 mm. The balloon catheter used to deliver the stent comes in lengths of 75 and 120 cm. A version of the system with the same name for the biliary tract is set to be unveiled the week of June 12, according to the company
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.